Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2019

Open Access 01-12-2019 | Prostate Cancer | Research article

Identification of recurrence marker associated with immune infiltration in prostate cancer with radical resection and build prognostic nomogram

Authors: Xin Rui, Siliang Shao, Li Wang, Jiangyong Leng

Published in: BMC Cancer | Issue 1/2019

Login to get access

Abstract

Background

Some historic breakthroughs have been made in immunotherapy of advanced cancer. However, there is still little research on immunotherapy in prostate cancer. We explored the relationship between immune cell infiltration and prostate cancer recurrence and tried to provide new ideas for the treatment of prostate cancer.

Methods

Prostate cancer RNA-seq data and clinical information were downloaded from the TCGA database and GEO database. The infiltration of 24 immune cells in tissues was quantified by ssGSEA. Univariate Cox regression analysis was used to screen for immune cell types associated with tumor recurrence, weighted gene co-expression network analysis (WGCNA) and LASSO were used to identify hub genes which regulate prognosis in patients through immune infiltration. Then, the nomogram was constructed based on the hub gene to predict the recurrence of prostate cancer, and the decision curve analysis (DCA) was used to compare the accuracy with the PSA and Gleason prediction models.

Result

Analysis showed that Th2 cells and Tcm related to prostate cancer recurrence after radical prostatectomy, and they are independent protective factors for recurrence. Through WGCNA and Lasso, we identified that NDUFA13, UQCR11, and USP34 involved in the infiltration of Th2 cells and Tcm in tumor tissues, and the expression of genes is related to the recurrence of patients. Based on the above findings, we constructed a clinical prediction model and mapped a nomogram, which has better sensitivity and specificity for prostate cancer recurrence prediction, and performed better in comparison with PSA and Gleason’s predictions.

Conclusion

The immune cells Th2 cells and Tcm are associated with recurrence of PCa. Moreover, the genes NDUFA13, UQCR11, and USP34 may affect the recurrence of PCa by affecting the infiltration of Th2 cells and Tcm. Moreover, nomogram can make prediction effectively.
Literature
1.
Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, Macintyre MF, Allen C, Hansen G, Woodbrook R, CJJO W. The global burden of cancer 2013. 2015;1(4):505.
2.
AJCACJfC J. Cancer statistics, 2016. 2010;63(1):11.
3.
Schiavina R, Bianchi L, Borghesi M, Briganti A, Brunocilla E, Carini M, Terrone C, Mottrie A, Dente D, MJIJoU G. Predicting survival in node-positive prostate cancer after open, laparoscopic or robotic radical prostatectomy: a competing risk analysis of a multi-institutional database. 2016;23(12).
4.
Gianluca I, Alessandra C, Elisabetta P, Alessandra M, Daniela DC, Rosaria B, Michaela B, Luana DM, Emilia G, BJCI P. Acute and late toxicity after three-dimensional conformal image-guided radiotherapy for localized prostate cancer. 2014;32(10):526–32.
5.
Kalogeridi MA, Kyrgias G, Zygogianni A, Kouvaris J, Theodorou K, Kelekis N, VJUJ K. Challenges and choices in prostate cancer irradiation: from the three dimensional conformal radiotherapy to the era of intensity modulated, image-guided and adaptive radiation treatment. 2014;11(6):1925–31.
6.
Hall J, JMc B, D T. Why patients choose prostatectomy or brachytherapy for localized prostate cancer: results of a descriptive survey. Urology. 2003;61(2):402–7.PubMedCrossRef
7.
Valerio M, Cerantola Y, Eggener SE, Lepor H, Polascik TJ, Villers A, Emberton M. New and established technology in focal ablation of the prostate: a systematic review. Eur Urol. 2017;71(1).PubMedCrossRef
8.
Jong DD, Verheul HMW, Bloemendal HJ, Klerk JMHD, Carducci MA, AJM E. New treatment options for patients with metastatic prostate cancer: what is the optimal sequence? Clin Genitourin Cancer. 2015;13(4):271–9.CrossRef
9.
Grossfeld GD, Stier DM, Flanders SC, Henning JM, Schonfeld W, Warolin K, PR C. Use of second treatment following definitive local therapy for prostate cancer: data from the caPSURE database. J Urol. 1998;160(4):1398–404.PubMedCrossRef
10.
Walsh PC. Follow-up prostate cancer treatments after radical prostatectomy: a population-based study. J Natl Cancer Inst. 1996;88(3–4):166–73.
11.
Bott SR. Management of recurrent disease after radical prostatectomy. Prostate Cancer Prostatic Dis. 2004;7(3):211–6.PubMedCrossRef
12.
Caroline R, Luc T, Igor B, Steven OD, Jeffrey Weber MD, Claus G, Celeste L, Jean-François B, Alessandro T, Jean-Jacques G: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
13.
Hossein B, Luis PA, Leora H, Spigel DR, Martin S, Ready NE, Chow LQ, Vokes EE, Enriqueta F, Esther HJNEJM. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. 2015;373(17):123–35.
14.
Hussein MRA, Mana AA, Musalam AO. Phenotypic characterization of the infiltrating immune cells in normal prostate, benign nodular prostatic hyperplasia and prostatic adenocarcinoma. J Experimental Pathology M. 2009;86(2):108–13.CrossRef
15.
Kiessling A, Füssel S, Wehner R, Bachmann M, Wirth MP, Rieber EP, Schmitza MJEU. Advances in specific immunotherapy for prostate cancer. 2008;53(4):694–708.
16.
17.
Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf A, Angell H, Fredriksen T, Lafontaine L, Berger AJI. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. 2013;39(4):782–95.
18.
Wedge DC, Gundem G, Mitchell T, Woodcock DJ, Martincorena I, Ghori M, Zamora J, Butler A, Whitaker H, Kote-Jarai ZJ. Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets. Nat Gene. 2018.
19.
Schatz A, Mian BM. Current and emerging trends in prostate cancer immunotherapy. Asian J Androl. 2017.
20.
Kibel ASJNEJM: Sipuleucel-T immunotherapy for castration-resistant prostate cancer. 2015.
21.
Higano CS, Schellhammer PF, Small EJ, Burch PA, John Nemunaitis MD, Yuh L, Provost N, Frohlich MWJ. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer. 2009;115(16):3670–9.PubMedCrossRef
22.
23.
Madan RA, Bilusic M, Heery C, Schlom J, Gulley JL Semin Oncol: Clinical evaluation of TRICOM vector therapeutic cancer vaccines 2012, 39(3):296–304.
24.
Hu H, Nan J, Sun Y, Zhu D, Xiao C, Wang Y, Zhu L, Wu Y, Zhao J, Wu R. Electron leak from NDUFA13 within mitochondrial complex I attenuates ischemia-reperfusion injury via dimerized STAT3. Proc Natl Acad Sci USA. 2017;114(45):11908–13.PubMedCrossRef
25.
Lin H, Lin T, Lin J, Yang M, Shen Z, Liu H, Zou Z, Zheng ZJG: Inhibition of miR-423-5p suppressed prostate cancer through targeting GRIM-19.
26.
Xu H, Ma J, Wu J, Chen L, Sun F, Qu C, Zheng D, Xu S. Gene expression profiling analysis of lung adenocarcinoma. Braz J Med Biol Res. 2016;49(3).
27.
Wang R, Li J, Zhao Y, Li Y, Yin L. Investigating the therapeutic potential and mechanism of curcumin in breast cancer based on RNA sequencing and bioinformatics analysis. Breast Cancer. 2018;25(2):206–12.PubMedCrossRef
28.
Poalas K, Hatchi EM, Cordeiro N, Dubois SM, Leclair HM, Leveau C, Alexia C, Gavard J, Vazquez A, Bidère N. Negative regulation of NF-κB signaling in T lymphocytes by the ubiquitin-specific protease USP34. Cell Commun Signal. 2013;11(1):25–5.PubMedCrossRef
29.
30.
Simon JB, Ofer M, Barbara S. The role of microRNAs in the control of innate immune response in cancer. JNCI. 2014;106(10):165–93.
31.
Levins KJ, Prendeville S, Conlon S, Buggy DJ, Anesth J. The effect of anesthetic technique on μ-opioid receptor expression and immune cell infiltration in breast cancer. 2018;32(6).
32.
33.
Liu M, Zhen X, Song H, Chen J, Sun X, Li X, Zhou J, Yan G, Ding L, Sun H. Low-dose lymphocyte immunotherapy rebalances the peripheral blood Th1/Th2/Treg paradigm in patients with unexplained recurrent miscarriage. Reprod Biol Endocrinol. 2017;15(1):95.PubMedPubMedCentralCrossRef
34.
Chamoto K, Al-Habsi M, Honjo T. Role of PD-1 in immunity and diseases. Curr Top Microbiol Immunol. 2017;410:75–97.PubMed
Metadata
Title
Identification of recurrence marker associated with immune infiltration in prostate cancer with radical resection and build prognostic nomogram
Authors
Xin Rui
Siliang Shao
Li Wang
Jiangyong Leng
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2019
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-019-6391-9

Other articles of this Issue 1/2019

BMC Cancer 1/2019 Go to the issue

Research article

Fascin-1 enhances experimental osteosarcoma tumor formation and metastasis and is related to poor patient outcome

Research article

STAT3 induces G9a to exacerbate HER3 expression for the survival of epidermal growth factor receptor-tyrosine kinase inhibitors in lung cancers

Technical advance

A new indocyanine green fluorescence lymphography protocol for identification of the lymphatic drainage pathway for patients with breast cancer-related lymphoedema

Research article

Cytotoxic effects of ex vivo-expanded natural killer cell-enriched lymphocytes (MYJ1633) against liver cancer

Case report

HPV insertional pattern as a personalized tumor marker for the optimized tumor diagnosis and follow-up of patients with HPV-associated carcinomas: a case report

Correction

Correction to: Bioinformatic exploration of OLFML2B overexpression in gastric cancer base on multiple analyzing tools
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits